Physician profile
Elena A Christofides
NPI 1306893433
$2,303,559.74
in general payments reported to CMS, 2019-2025
67 companies · $424K in 2025
The $424K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $403K · 2020: $291K · 2021: $308K · 2022: $353K · 2023: $225K · 2024: $299K · 2025: $424K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $502K · Honoraria: $260K · Travel and Lodging: $114K · Consulting Fee: $45K · Food and Beverage: $24K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,500 · Education: $1,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $502,140.67 |
| Honoraria | $259,806.98 |
| Travel and Lodging | $114,067.89 |
| Consulting Fee | $44,703.72 |
| Food and Beverage | $24,398.78 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,500.00 |
| Education | $1,209.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $589,905.50 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $327,601.21 | 2019-2025 | Korlym |
| Novo Nordisk INC | $223,037.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $202,478.06 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $156,526.81 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Recordati_rare_diseases_inc. | $155,447.07 | 2020-2025 | Isturisa, Signifor Lar |
| Abbvie INC. | $134,641.73 | 2019-2025 | Synthroid, Ubrelvy |
| Ascendis Pharma Endocrinology INC | $124,148.00 | 2022-2025 | Yorvipath, Skytrofa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114,055.97 | 2019-2024 | Jardiance |
| Amryt Pharma Holdings Ltd | $66,144.10 | 2020-2023 | Mycapssa, Myalept |
| Astrazeneca Pharmaceuticals Lp | $56,578.45 | 2019-2023 | Farxiga |
| Chiesi USA, INC. | $33,628.32 | 2024-2025 | Mycapssa, Myalept |
| Horizon Therapeutics Plc | $16,549.99 | 2019-2023 | Tepezza |
| Shire North American Group INC | $15,400.52 | 2019 | |
| Alfasigma USA, INC. | $13,553.19 | 2021-2022 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiasma, INC. | $11,980.14 | 2021 | |
| Merck Sharp & Dohme LLC | $10,330.20 | 2019-2021 | |
| Eli Lilly and Company | $9,526.64 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $8,797.35 | 2021-2025 | |
| Mannkind Corporation | $5,892.53 | 2022 | |
| Madrigal Pharmaceuticals | $5,817.71 | 2025 | Rezdiffra |
| Medicure Pharma INC. | $4,511.19 | 2019-2020 | |
| Zealand Pharma US, INC. | $3,117.06 | 2021-2022 | |
| Abbott Laboratories | $2,911.93 | 2019-2025 | Freestyle Libre 3 |
| Pfizer INC. | $2,531.02 | 2019-2024 | |
| Strongbridge US INC. | $1,800.00 | 2020 | |
| Alexion Pharmaceuticals, INC. | $961.55 | 2022-2025 | Strensiq |
| Dexcom, INC. | $786.13 | 2019-2025 | Dexcom G6 Transmitter |
| Ipsen Innovation | $675.00 | 2024 | Iqirvo |
| Merz North America, INC. | $459.92 | 2021-2022 | |
| Radius Health, INC. | $396.62 | 2019-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $380.30 | 2023-2025 | |
| Axsome Therapeutics, INC. | $378.27 | 2024-2025 | Auvelity, Sunosi |
| Amgen INC. | $297.63 | 2019-2025 | Tepezza, Evenity, Prolia |
| Amarin Pharma, INC. | $257.73 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $231.81 | 2019-2023 | Livalo |
| Aegerion Pharmaceuticals, INC. | $181.06 | 2019 | |
| Kyowa Kirin, INC. | $167.28 | 2023-2025 | Crysvita |
| Astellas Pharma US INC | $161.59 | 2023-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $119.58 | 2019-2020 | |
| Allergan, INC. | $114.81 | 2019 | |
| Endo Pharmaceuticals INC. | $98.43 | 2019-2021 | |
| Tandem Diabetes Care, INC. | $87.75 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $86.34 | 2022 | |
| Jazz Pharmaceuticals INC. | $85.18 | 2021 | |
| Esperion Therapeutics, INC. | $82.17 | 2024-2025 | Nexletol |
| Eusa Pharma (US) LLC | $72.27 | 2022 | |
| Valeritas, INC. | $72.11 | 2019 | |
| Sequel Med Tech, LLC | $58.36 | 2024-2025 | Twiist |
| Rhythm Pharmaceuticals, INC. | $54.89 | 2023-2025 | Imcivree, Imcivree |
| Clarus Therapeutics INC. | $53.57 | 2021 | |
| Ibsa Pharma INC. | $51.30 | 2019-2024 | Tirosint, Licart, Tirosint |
| Antares Pharma, INC. | $49.94 | 2021 | |
| Neurocrine Biosciences, INC. | $42.94 | 2024-2025 | Crenessity |
| Beta Bionics, INC. | $34.96 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Currax Pharmaceuticals LLC | $33.32 | 2019-2022 | |
| Ascensia Diabetes Care US INC. | $22.79 | 2025 | |
| Sun Pharmaceutical Industries INC. | $18.17 | 2020 | |
| Bigfoot Biomedical INC | $17.57 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.38 | 2020 | |
| Emd Serono, INC. | $14.09 | 2019 | |
| Nevro Corp. | $14.00 | 2023 | Senza |
| Acerus Pharmaceuticals Corporation | $12.14 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$109,967.83 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elena Christofides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.